Genscript appears attractive - not just Legend's product pipeline and strong partnerships; but also Genscript's stub ops have been performing well. I wouldn't long/short this. Perhaps an outright long
What is covered in the Full Insight:
Bullish and Bearish Points
Conclusions First
Legend Biotech and Carvykti
Mergers and Acquisitions Process
Genscript and Legend's Financial Performance
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.